Resmed Inc dividend calculator – ResMed Declares Quarterly Dividend of $0.44/Share in Line with Previous
February 13, 2023
Trending News 🌥️
Resmed Inc dividend calculator – RESMED ($NYSE:RMD): ResMed Inc. is a leading medical technology company that is focused on developing, manufacturing and marketing products and services that improve the quality of life for people with sleep apnea, COPD and other chronic respiratory diseases. ResMed Inc. has recently announced a quarterly dividend of $0.44 per share, which is in line with the previous dividend. The dividend is payable on March 16 to shareholders of record on February 9, and the ex-dividend date is February 8. This dividend provides investors with a great way to increase their portfolio returns and to generate income through their stock investments. For more information on ResMed’s dividends, investors can visit the RMD Dividend Scorecard, Yield Chart, and Dividend Growth.
This information can provide investors with a better understanding of the performance of the company’s dividends, as well as insight into potential future dividends that may be paid out. The company’s announcement of a quarterly dividend of $0.44 per share is in line with previous dividends and offers investors an attractive option for income generation through their stock investments. Therefore, investors should seriously consider adding ResMed Inc. to their portfolio.
Dividends – Resmed Inc dividend calculator
Last year, ResMed Inc. issued an annual dividend per share of 1.72, 1.68, and 1.56 USD respectively. The dividend yields for 2021 to 2023 are expected to be 0.75%, 0.69%, and 0.77%. The average dividend yield is estimated to be 0.74%. This shows that the company is committed to providing a consistent dividend return to its investors. The company continues to focus on its long-term growth initiatives, including leveraging its strong financial position and investing in innovative products and solutions.
ResMed Inc. also continues to evaluate and pursue opportunities that extend and improve its market reach and overall financial performance. ResMed Inc. is committed to delivering high-quality products and services that meet the needs of its customers and partners. The company is focused on creating value for its shareholders through its long-term growth initiatives and dividend payments. This commitment has enabled the company to further strengthen its position in the medical device industry and provide sustainable returns for its investors.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Resmed Inc. More…
| Total Revenues | Net Income | Net Margin |
| 3.76k | 809.47 | 21.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Resmed Inc. More…
| Operations | Investing | Financing |
| 370.22 | -1.19k | 887.66 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Resmed Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.68k | 2.94k | 23.44 |
Key Ratios Snapshot
Some of the financial key ratios for Resmed Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.6% | 14.8% | 28.0% |
| FCF Margin | ROE | ROA |
| 5.9% | 18.4% | 9.9% |
Stock Price
Following the announcement, the stock opened at $220.0 and closed at $224.4, up by 1.4% from last closing price of 221.5. This is the third consecutive quarter in which RESMED INC has declared a dividend, and the second consecutive quarter in which the dividend has remained unchanged, indicating confidence in the company’s continued growth and financial health. The increased dividend is a sign of financial strength and a belief in the company’s future prospects. Overall, RESMED INC’s quarterly dividend payment is a sign of confidence in their business model and future growth.
The company’s strong financial position and continued success in the stock market point to a bright future for the company and its shareholders. This quarter’s dividend payment serves as another reminder of RESMED INC’s commitment to returning value to shareholders. Live Quote…
Analysis
GoodWhale has conducted an analysis of RESMED INC‘s financials and found that it is a medium risk investment. Risk Rating takes into account various financial and business aspects, and RESMED INC has been assessed as being of medium risk. GoodWhale has detected 1 risk warning in RESMED INC’s balance sheet, although this needs to be explored further. To get more insight into this warning and the company’s financial health, users will need to become registered users of GoodWhale. Risk Rating is an important measure of a company’s financial health, and RESMED INC has been determined to be a medium risk investment. This means that while the company has some strong financials, there are also some potential risks that must be evaluated further before investing. A medium risk rating indicates that RESMED INC is neither overly safe nor overly risky, but rather somewhere in between. It is important for investors to be aware of the risk warnings present in a company’s balance sheet. GoodWhale has detected one such warning in RESMED INC’s balance sheet, although it is recommended that users become registered users of GoodWhale to gain a deeper understanding of this risk warning and the company’s overall financial situation. Overall, RESMED INC is a medium risk investment in terms of financial and business aspects. It is important to consider the risks associated with investing in the company before making a decision. GoodWhale can help investors understand the potential risks associated with RESMED INC by offering further analysis and warning notifications. More…
Peers
ResMed’s competitors include Natus Medical Inc, Sanara MedTech Inc, and Avita Corp.
– Natus Medical Inc ($NASDAQ:SMTI)
As of 2022, Sanara MedTech Inc has a market cap of 227.36M and a Return on Equity of -22.91%. The company is a medical device company that develops and manufactures products for the treatment of chronic wounds and other conditions.
– Sanara MedTech Inc ($TPEX:4735)
Avita Corp is a biotechnology company that develops, manufactures, and markets products based on regenerative medicine. The company’s products are used to treat a variety of conditions, including burns, wounds, and skin diseases. Avita’s products are sold in over 30 countries worldwide. The company has a market cap of 1.21B as of 2022 and a return on equity of 9.62%.
Summary
Investing in ResMed Inc. is a solid option for investors looking for a reliable return. The company has a strong financial position and a consistent dividend policy, recently declaring a quarterly dividend of $0.44/share. Its products are in high demand globally, and the company has grown its revenues year over year for the past few years.
Its share price has been relatively stable over the long term, making it an attractive option for conservative investors who are looking for a steady return without high risk. The company has also made strategic acquisitions to expand its product offerings and increase its presence in global markets, positioning it well to continue its growth trajectory.
Related Posts
Recent Posts
